Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001013762-25-001860
Filing Date
2025-03-25
Accepted
2025-03-25 08:57:47
Documents
15
Period of Report
2023-12-11
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 4 TO FORM 8-K ea0235342-8ka4_aditxt.htm   iXBRL 8-K/A 34573
2 AUDITED CONSOLIDATED FINANCIAL STATEMENTS OF EVOFEM BIOSCIENCES, INC. AND SUBSID ea023534201ex99-1_aditxt.htm EX-99.1 556582
3 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEAR END ea023534201ex99-2_aditxt.htm EX-99.2 258410
  Complete submission text file 0001013762-25-001860.txt   1152169

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adtx-20231211.xsd EX-101.SCH 3008
5 XBRL LABEL FILE adtx-20231211_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE adtx-20231211_pre.xml EX-101.PRE 22354
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0235342-8ka4_aditxt_htm.xml XML 8567
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39336 | Film No.: 25766044
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)